Positive news for Shire’s ADHD treatment Elvanse

Rebecca Aris


Approvals for Shire’s attention deficit / hyperactivity disorder (ADHD) treatment Elvanse® is imminent in eight European states.

Elvanse is specifically indicated as part of a comprehensive treatment programme for ADHD in children aged 6 years of age and over when response to previous treatment is insuficient. It is currently the most prescribed branded ADHD medicine in the US, where it available under the trade name Vyvanse®.

“As all ADHD patients are different and will vary in their responses to the available treatments, we believe introducing Elvanse will provide physicians with a broader range of options…we will now work closely with the pricing and reimbursement authorities in the respective countries to ensure that Elvanse is made available to patients as soon as possible”.

Angus Russell, Chief Executive, Shire

 The timing of the drug being made available will vary from country to country.


Related news:

Shire ADHD drug Elvanse close to Europe approval (Pharma Times)

Reference links:

Press release (Shire)


Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.